Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH

Newsletter